Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866918 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
NCT00866918 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 106 participants.
The verdict
NCT00866918, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
Study Summary
This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Arsenic Trioxide
- OTHER Diagnostic Laboratory Biomarker Analysis
- DRUG Mercaptopurine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2009-03-09 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866918
The ClinicalTrials.gov registry entry for NCT00866918 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cytarabine is the first listed.
NCT00866918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866918 about?
NCT00866918 is a clinical study titled "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia". This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from ...
What is the current status of trial NCT00866918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2009-03-09. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT00866918?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG), Arsenic Trioxide (DRUG), Diagnostic Laboratory Biomarker Analysis (OTHER), Mercaptopurine (DRUG).
Who is sponsoring clinical trial NCT00866918?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.